AR079049A1 - Combinacion terapeutica que comprende un inhibidor de cdc7 y un agente antineoplasico - Google Patents
Combinacion terapeutica que comprende un inhibidor de cdc7 y un agente antineoplasicoInfo
- Publication number
- AR079049A1 AR079049A1 ARP100104238A AR079049A1 AR 079049 A1 AR079049 A1 AR 079049A1 AR P100104238 A ARP100104238 A AR P100104238A AR 079049 A1 AR079049 A1 AR 079049A1
- Authority
- AR
- Argentina
- Prior art keywords
- inhibitor
- therapeutic combination
- antineoplastic agent
- agent
- topoisomerase
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 4
- 229940034982 antineoplastic agent Drugs 0.000 title abstract 2
- 239000002246 antineoplastic agent Substances 0.000 title abstract 2
- 230000001225 therapeutic effect Effects 0.000 title abstract 2
- 102100034744 Cell division cycle 7-related protein kinase Human genes 0.000 title 1
- 101000945740 Homo sapiens Cell division cycle 7-related protein kinase Proteins 0.000 title 1
- 230000002152 alkylating effect Effects 0.000 abstract 2
- 102000010565 Apoptosis Regulatory Proteins Human genes 0.000 abstract 1
- 108010063104 Apoptosis Regulatory Proteins Proteins 0.000 abstract 1
- 229940124087 DNA topoisomerase II inhibitor Drugs 0.000 abstract 1
- 102000009465 Growth Factor Receptors Human genes 0.000 abstract 1
- 108010009202 Growth Factor Receptors Proteins 0.000 abstract 1
- 229940079156 Proteasome inhibitor Drugs 0.000 abstract 1
- 101710183280 Topoisomerase Proteins 0.000 abstract 1
- 239000000317 Topoisomerase II Inhibitor Substances 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000002256 antimetabolite Substances 0.000 abstract 1
- 239000003080 antimitotic agent Substances 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003102 growth factor Substances 0.000 abstract 1
- 239000003207 proteasome inhibitor Substances 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La presente invencion proporciona una combinacion terapéutica que comprende (a) un compuesto de formula (1) divulgado en la memoria y (b) uno o más agentes antineoplásicos seleccionados del grupo consistente en un agente alquilante o de tipo alquilante, un agente antimetabolito, un inhibidor de topoisomerasa 1, un inhibidor de topoisomerasa II, un inhibidor de un factor de crecimiento o de un receptor de un factor de crecimiento, un agente antimitotico, un inhibidor del proteasoma, un inhibidor de una proteína antiapoptotica y un anticuerpo dirigido contra una proteína de la superficie celular, donde los ingredientes activos están presentes en cada caso en forma libre o en la forma de una sal farmacéuticamente aceptable o cualquier hidrato de los mismos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09176370 | 2009-11-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR079049A1 true AR079049A1 (es) | 2011-12-21 |
Family
ID=43501061
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP100104238 AR079049A1 (es) | 2009-11-18 | 2010-11-17 | Combinacion terapeutica que comprende un inhibidor de cdc7 y un agente antineoplasico |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US9119877B2 (es) |
| EP (1) | EP2501385B1 (es) |
| JP (1) | JP2013511487A (es) |
| CN (1) | CN102753176B (es) |
| AR (1) | AR079049A1 (es) |
| ES (1) | ES2625492T3 (es) |
| TW (1) | TW201127384A (es) |
| WO (1) | WO2011061222A1 (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX344474B (es) | 2011-03-31 | 2016-12-16 | Carna Biosciences Inc | Nuevos derivados de furanona. |
| US8912200B2 (en) | 2011-07-28 | 2014-12-16 | Nerviano Medical Sciences S.R.L. | Alkynyl substituted pyrimidinyl-pyrroles active as kinases inhibitors |
| US20190269675A1 (en) | 2014-01-28 | 2019-09-05 | Buck Institute for Research and Aging | Treatment of parkinson's disease and other conditions caused or mediated by senescent astrocytes using small molecule senolytic agents |
| US10328058B2 (en) | 2014-01-28 | 2019-06-25 | Mayo Foundation For Medical Education And Research | Treating atherosclerosis by removing senescent foam cell macrophages from atherosclerotic plaques |
| US20170216286A1 (en) | 2014-01-28 | 2017-08-03 | Mayo Foundation For Medical Education And Research | Killing senescent cells and treating senescence-associated conditions using a src inhibitor and a flavonoid |
| SG11201606239UA (en) | 2014-01-28 | 2016-08-30 | Buck Inst For Res On Aging | Methods and compositions for killing senescent cells and for treating senescence-associated diseases and disorders |
| EP3100742B1 (en) | 2014-01-31 | 2020-05-20 | Carna Biosciences Inc. | Anticancer agent composition comprising a cdc7 inhibitor and a wee1 inhibitor |
| WO2019165473A1 (en) * | 2018-02-26 | 2019-08-29 | Sierra Oncology, Inc | Methods of treatment of cancer comprising cdc7 inhibitors |
| GB201807147D0 (en) * | 2018-05-01 | 2018-06-13 | Oncologica Uk Ltd | Therapeutic combination |
| US12533353B2 (en) | 2018-09-24 | 2026-01-27 | Carna Biosciences, Inc. | Methods of treatment of cancer comprising CDC7 inhibitors |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5750737A (en) * | 1996-09-25 | 1998-05-12 | Sisti; Nicholas J. | Method for paclitaxel synthesis |
| US8263604B2 (en) | 2006-03-27 | 2012-09-11 | Nerviano Medical Sciences S.R.L. | Pyridyl- and pyrimidinyl-substituted pyrrole-, thiophene- and furane-derivatives as kinase inhibitors |
| TWI426074B (zh) * | 2008-04-30 | 2014-02-11 | Nerviano Medical Sciences Srl | ５－（２－胺基－嘧啶－４－基）－２－芳基－１ｈ－吡咯－３－羧醯胺之製造方法 |
-
2010
- 2010-11-16 TW TW99139324A patent/TW201127384A/zh unknown
- 2010-11-17 ES ES10781875.9T patent/ES2625492T3/es active Active
- 2010-11-17 AR ARP100104238 patent/AR079049A1/es unknown
- 2010-11-17 CN CN201080052245.9A patent/CN102753176B/zh not_active Expired - Fee Related
- 2010-11-17 JP JP2012539315A patent/JP2013511487A/ja active Pending
- 2010-11-17 US US13/509,625 patent/US9119877B2/en active Active
- 2010-11-17 WO PCT/EP2010/067675 patent/WO2011061222A1/en not_active Ceased
- 2010-11-17 EP EP10781875.9A patent/EP2501385B1/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP2501385A1 (en) | 2012-09-26 |
| HK1177889A1 (en) | 2013-08-30 |
| CN102753176B (zh) | 2014-07-16 |
| US20120276093A1 (en) | 2012-11-01 |
| TW201127384A (en) | 2011-08-16 |
| WO2011061222A1 (en) | 2011-05-26 |
| CN102753176A (zh) | 2012-10-24 |
| JP2013511487A (ja) | 2013-04-04 |
| US9119877B2 (en) | 2015-09-01 |
| ES2625492T3 (es) | 2017-07-19 |
| EP2501385B1 (en) | 2017-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR079049A1 (es) | Combinacion terapeutica que comprende un inhibidor de cdc7 y un agente antineoplasico | |
| CY1123255T1 (el) | Σχημα δοσολογιας για εναν αγωνιστη υποδοχεα s1p | |
| AR076784A1 (es) | Combinacion terapeutica que comprende un inhibidor de plk1 y un agente antineoplasico | |
| GT200900283A (es) | "terapia de combinación con un compuesto actuando como un inhibidor del receptor adp plaquetario". | |
| ECSP067080A (es) | DIFENILIMIDAZOPIRIMIDINA Y AMINAS IMIDAZOL COMO INHIBIDORES DE ß-SECRETASA | |
| ECSP045253A (es) | Derivados de 5-feniltiazol y uso como inhibidores de pi3 cinasa | |
| SV2009003281A (es) | Inhibidores espiro cetona de acetil-coa carboxilasa.0 | |
| ECSP066950A (es) | Combinaciones de glicopirrolato y agonistas del adrenoceptor-beta2 | |
| PA8720801A1 (es) | Nuevas combinaciones terapeuticas para el tratamiento de la depresion | |
| UY29086A1 (es) | Nuevas composiciones farmacéuticas para el tratamiento de trastornos hiperproliferativos. | |
| ECSP11011189A (es) | Moduladores de los receptores tipo toll | |
| CL2016002589A1 (es) | Uso del compuesto genz-112638 (eliglustat), inhibidor de glucosilceramida sintasa, en el tratamiento de la enfermedad de gaucher y enfermedad de fabry (divisional de solicitud 201201348). | |
| NO20076347L (no) | Nye regimer for orale monofasiske befruktningshindrene midler | |
| HN2005000795A (es) | Pirimidinas como antagonistas del receptor de prostaglandina d2 | |
| ECSP067076A (es) | Derivados de pirimidina urea como inhibidores de la quinasa | |
| NO20091395L (no) | Nye tiofenderivater | |
| LU92550I2 (fr) | Lurasidone, facultativement sous forme de sa base libre ou de ses sels pharmaceutiquement acceptables | |
| ES2531093T3 (es) | Procedimiento de preparación de halogenuros de N-alquil-naltrexona | |
| CR9846A (es) | 2-amino-7,8-dihidro-6h-pirido[4,3-d]pirimidina-5-onas | |
| CO6321225A2 (es) | Particulas portadoras sólidas para mejorar la procesabilidad de un agente farmacéutico | |
| CL2007001752A1 (es) | Compuesto 4-[5(2-amino-etansulfonil)-isoquinolin-7-il]-fenolo una sal farmaceuticamente aceptable o un hidrato o la sal del mismo;composicion farmaceutica que comprende a dicho compuesto,composicion farmaceutica liofilizada;y uso del compuesto como antineiplasico y/o antiviral. | |
| UY30736A1 (es) | Compuestos quimicos 537 | |
| ECSP078057A (es) | Formulaciones de estrógenos conjugados y bazedoxifeno | |
| AR067813A1 (es) | Fenilendiaminas sustituidas como inhibidores de l ainteraccion entre mdm2 y p53 | |
| BRPI0916540B8 (pt) | inibidores do canal de ânion de superficíe de plasmódio como agentes antimaláricos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |